Clinical trial NCT01114503: A Safety and Tolerability Study of Otelixizumab in Thyroid Eye Disease
Official title: A Randomised, Comparator Controlled, Two Part, Open-label Study to Evaluate the Safety, Tolerability and Pharmacodynamics of Multiple Doses of Otelixizumab in Patients With Thyroid Orbitopathy
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Graves Ophthalmopathy
Keywords: GSK2136525
Pharmacodynamics
Safety
Otelixizumab
Thyroid eye disease
Graves' ophthalmopathy
Repeat dose
Intravenous infusion
Tolerability
EUGOGO
Lead sponsor: GlaxoSmithKline
Sponsor class: INDUSTRY
First posted: 2010-05-03
Enrollment: 2
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to investigate the safety and tolerability of otelixizumab in patients with Graves' ophthalmopathy (thyroid eye disease). There is currently no alternative therapy available for this condition other than treatment with steroids, or radiotherapy and surgery. The study also includes a comparison of the current steroid treatment, methylprednisolone, with the proposed new otelixizumab treatment.

Detailed description: This is a study of otelixizumab, a monoclonal antibody (MAb) directed against the human lymphocyte antigen CD3 (a protein found on a certain type of white blood cell). This will be an open-label, comparator-controlled, two part study to evaluate the safety and tolerability of otelixizumab in patients with Graves' ophthalmopathy (GO). It will also look to see if otelixizumab affects GO and how it works compared to methylprednisolone (the standard treatment for active GO).

In Part A, between one and four groups of 5 patients will receive doses of otelixizumab administered over 8 days. The first dose level will provide a low cumulative dose, this low dose level has been safely administered in previous studies. Safety and clinical response data will be reviewed after 8 weeks, if no clinical response is seen and there are no safety concerns, the dose of otelixizumab will be increased and a new group of subjects will enter Part A. In subsequent groups cumulative medium low, medium high, and high doses of otelixizumab may be investigated. However if a clinical response is seen at the lowest dose the study will move directly to Part B.

In Part B, patients will receive either otelixizumab at the dose set from Part A, over 8 days (5 patients) or methylprednisolone weekly for 12 weeks (5 patients). All dosing will be by intravenous infusion. All participants will undergo long term safety evaluation for 48 months.

Key assessments include vital signs, 12-lead ECG, liver function tests, thyroid function, viral monitoring, monitoring of cortisol and ACTH levels, laboratory safety tests and adverse event (side effect) data. Assessment of GO severity will be evaluated using recommended assessments including clinical activity assessments and quality of life questionnaires. Measurements of exploratory biomarkers (proteins found naturally in the blood) are also included in this study.

Eligibility criteria: Inclusion Criteria:

* Male or female between 18 and 75 years of age inclusive
* A female subject is eligible to participate if she is of:
* Non-childbearing potential defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea \[in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) \> 40 mIU/ml and estradiol \<40 pg/ml (\<140 pmol/L) is confirmatory\].
* Child-bearing potential and agrees to use one of the agreed contraception methods listed in the protocol for an appropriate period of time to sufficiently minimize the risk of pregnancy at that point. Female subjects must agree to use contraception for at least 2 weeks prior to dosing and for at least 6 months after the last dose.
* Male subjects must agree to use one of the contraception methods listed in the protocol. This criterion must be followed from the time of the first dose of study medication until at least 60 days after the last dose.
* Blood test of liver function within normal range
* Body mass index within 18.5 - 35 kg/m2 inclusive
* Capable of giving informed consent and agreement to comply with the study restrictions
* 12-lead ECG within normal limits
* fT4 blood levels within reference range for at least 2 months
* Active Graves' Ophthalmopathy (GO) with a Clinical Activity Score (CAS) of \>/= 3 out of 7
* Moderately severe GO (as defined by EUGOGO guidelines)
* No previous immunosuppressive treatment for GO
* Subject is seropositive for EBV with \<10,000 copies of EBV DNA per 10\^6 lymphocytes (qPCR) or seronegative with no evidence of acute EBV infection (asymptomatic, negative EBV IgM and EBV viral load of \<10,000 per 10\^6 lymphocytes)
* The subject has no current or prior malignancy, other than non-melanoma skin cancer (subject must have had fewer than 5 occurrences of non-melanoma skin cancer, and the last occurrence must not be within 3 months of study entry)

Exclusion Criteria:

* A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening
* Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones)
* Positive pre-study drug/alcohol screen. A minimum list of drugs that will be screened for include amphetamines, barbiturates, cocaine, opiates, cannabinoids and benzodiazepines
* Positive test for HIV antibody
* Positive test for syphilis
* History of regular alcohol consumption within 6 months of the study defined as:
* an average weekly intake of greater than 21 units or an average daily intake of greater than 3 units (males), or
* an average weekly intake of greater than 14 units or an average daily intake of greater than 2 units (females)
* Participation in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer) or planning to take any investigational drug for the planned duration of study participation (6 months after the last dose of study drug)
* Exposure to more than four new chemical entities within 12 months prior to the first dosing day
* History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation
* Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period
* Pregnant females as determined by positive (serum or urine) hCG test at screening or prior to dosing, or lactating females
* Currently receiving or has received corticosteroids or other immunosuppressive agents within the last 3 months
* Evidence of optic neuropathy and/or corneal breakdown
* Immunization with a vaccine within 30 days before the first dose of study drug or requires a vaccine within 30 days after the last dose of study drug
* A CD4+ lymphocyte count outside the range of 0.53 - 1.76 × 109/L during screening
* Significant systemic infection during the 6 weeks before the first dose of study drug
* Received a course of oral antibiotics within 2 weeks of dosing day one
* History of recurrent or chronic infection
* Subject has had a splenectomy
* Subjects with a screening chest X-ray suggestive of TB without documentation of adequate TB treatment
* Any major surgical procedure within the 8 weeks before signing the consent form, or planning to undergo any such surgery within the 3 months after the last dose of study drug
* Clinically significant cardiovascular and/or cerebrovascular disease
* Predisposition to thromboembolic disease, or thromboembolic event (excluding superficial) in past 12 months
* Uncontrolled medical conditions: Significant concurrent, uncontrolled medical condition including, but not limited to renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, neurological, cerebral psychiatric disease, or evidence of demyelinating disease
* A condition or situation that, in the investigator's judgment, is likely to cause the subject to be unable or unwilling to participate in study procedures or to complete all scheduled assessments
* Clinically significant abnormal laboratory values during the Screening period, other than those due to GO. Abnormal values are permitted if, upon re-test, the abnormality was resolved
* Unwillingness or inability to follow the procedures outlined in the protocol
* Mentally or legally incapacitated

Primary outcomes:
measure: Number of Participants With at Least One Adverse Event (AE), Serious Adverse Event (SAE), or Drug-related Adverse Event
timeFrame: Up to Month 24 (Long term follow-up)
measure: Number of Participants With Laboratory Clinical Chemistry Abnormalities Meeting the Criteria for Potential Clinical Concern (PCC)
timeFrame: Up to Month 24 (Long term follow-up)
measure: Number of Participants With Laboratory Hematology Abnormalities Meeting the Criteria for PCC
timeFrame: Upto Month 24 (Long term follow-up)
measure: Number of Participants With Laboratory Urinalysis Abnormalities Meeting the Criteria for PCC
timeFrame: Up to Month 24 (Long term follow-up)
measure: Number of Participants With Thyroid Function Assessment, Hormone and Glucose Assay Abnormalities Meeting the Criteria for PCC
timeFrame: Up to Week 24
measure: Number of Participants With Vital Signs Abnormalities Meeting the Criteria for PCC
timeFrame: Up to Month 24 (Long term follow-up)
measure: Number of Participants With Electrocardiogram (ECG) Abnormalities Meeting the Criteria for PCC
timeFrame: Screening (Day -35 to Day -1)
measure: Number of Participants With an Epstein Barr Virus (EBV) Viral Load Abnormalities Meeting the Criteria for PCC
timeFrame: Week 2 to Week 12
measure: Individual Absolute Circulating Peripheral T Lymphocytes (T-cells), CD4+ and CD8+ Subset Counts
timeFrame: Up to Week 24
measure: Percentage of Circulating Peripheral T-cells, CD4+ and CD8+ Subset Counts
timeFrame: Up to Week 24
measure: Assessment of CD3/T-cell Receptor (TCR) Complex Saturation and Modulation
timeFrame: Up to Week 24
Secondary outcomes:
measure: Change From Baseline for Individual Scores at Week 12 Incorporated in the European Group on Graves' Orbitopathy (EUGOGO) Assessment Including, Eyelid Swelling, Clinical Activity Score (CAS) Score, Proptosis, Lid Width and Diplopia
timeFrame: Baseline (Day 1, pre dose) and Week 12
measure: Change From Baseline for Participant-reported Health Related Quality of Life (QoL) Questionnaires of Short Form 36 ( SF-36) and Graves Ophthalmopathy (GO) QoL
timeFrame: Baseline (Day 1, pre dose) to Week 24
measure: Change From Baseline Measurement of Orbital Volume as Measured by Computed Tomography (CT) Scan
timeFrame: Baseline (Screening), Week 12 and Week 24
measure: Assessment of Anti-otelixizumab Antibodies
timeFrame: Up to Month 12
measure: Assessment of Circulating Cytokines of Interleukin 6 (IL6), IL10, Interferon Gamma (IFNγ) and Tumor Necrosis Factor Alpha (TNFα) up to 2 Weeks
timeFrame: Up to Week 2
measure: Assessment of Exploratory Biomarkers
timeFrame: Up to Week 24
measure: Assessment of Exploratory Biomarkers of Ribonucleic Acid (RNA) Transcription Analysis of Peripheral Blood
timeFrame: Up to Week 24
Other outcomes:
Locations:
city: Newcastle upon Tyne
country: United Kingdom
facility: GSK Investigational Site
Study officials:
affiliation: GlaxoSmithKline
name: GSK Clinical Trials
role: STUDY_DIRECTOR
References: